Thymosin Beta-4 vs XTRA
The nomenclature surrounding thymosin beta-4 (TB-4) is among the most confusing in peptide research. “TB-500” is a veterinary supplement brand name for a thymosin beta-4 fragment, while “XTRA” is another supplement brand marketing a thymosin beta-4 fragment. All three terms — TB-4, TB-500, and XTRA — ultimately refer to the same or overlapping peptides derived from the 43-amino acid thymosin beta-4 protein. The differences lie in fragment length, manufacturing quality, and regulatory status rather than fundamental molecular identity.
Molecular Identity
Section titled “Molecular Identity”Thymosin Beta-4 (Full-Length)
Section titled “Thymosin Beta-4 (Full-Length)”Thymosin beta-4 (TB-4) is a 43-amino acid acidic peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES) originally isolated from calf thymus. It is a member of the thymosin β family and serves as the major G-actin sequestering protein in mammalian cells, regulating:
- Actin polymerization: Sequesters monomeric G-actin, preventing spontaneous polymerization
- Cell migration: Promotes cell motility through actin cytoskeleton remodeling
- Wound healing: Stimulates angiogenesis, cell migration, and tissue repair
- Anti-inflammatory effects: Modulates macrophage and neutrophil function
- Cardioprotection: Protects cardiomyocytes from ischemia-reperfusion injury
TB-500
Section titled “TB-500”TB-500 is a veterinary supplement containing a synthetic fragment of thymosin beta-4. The designation “500” is misleading — it does not refer to molecular weight, amino acid count, or dosage. TB-500 typically contains a fragment spanning approximately amino acids 1–19 (fragment 1-19) or amino acids 17–39 (fragment 17-39) of the full-length TB-4 sequence. The exact fragment varies by manufacturer:
- Fragment 1-19: Ac-SDKPDMAEIEKFDKSKLK (19 amino acids, MW ~2,050 Da)
- Fragment 17-39: KLKKTETQEKNPLPSKETIEQEKQAGES (23 amino acids, MW ~2,540 Da)
TB-500 is marketed for equine and canine use to enhance recovery from musculoskeletal injuries. It is not FDA-approved for any indication in any species.
XTRA is another supplement brand marketing thymosin beta-4 fragments. Like TB-500, XTRA does not contain full-length TB-4 but rather a synthetic fragment. The most common formulation includes:
- Fragment 1-43 (full-length TB-4): Some XTRA products claim to contain full-length TB-4
- Fragment 1-19: The most commonly available form
- Fragment 17-39: Alternative formulation
The inconsistency in fragment composition between manufacturers and even between batches from the same manufacturer is a significant quality concern.
Comparison Table
Section titled “Comparison Table”| Property | Thymosin β-4 (Full-Length) | TB-500 (Fragment) | XTRA (Fragment) |
|---|---|---|---|
| Amino acid count | 43 | 19–23 (varies) | 19–43 (varies) |
| Molecular weight | ~4,921 Da | ~2,050–2,540 Da | ~2,050–4,921 Da |
| Sequence | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES | Fragment 1-19 or 17-39 | Fragment 1-19, 17-39, or 1-43 |
| Manufacturing grade | Pharmaceutical (research) | Veterinary supplement | Supplement |
| Regulatory status | Investigational (research) | Not approved (veterinary supplement) | Not approved (supplement) |
| GMP manufacturing | Yes (research grade) | No (supplement grade) | No (supplement grade) |
| Purity verification | HPLC-verified (>95%) | Variable (80–95%) | Variable (70–95%) |
| Primary use | Research, clinical trials | Equine/canine recovery | Human supplement (non-approved) |
| Supply source | Research chemical suppliers, pharmacies | Veterinary suppliers | Online supplement vendors |
| Stability data | Published (lyophilized: 24+ months) | Limited | Limited |
Mechanism of Action (Common to All Forms)
Section titled “Mechanism of Action (Common to All Forms)”All forms of TB-4 (full-length or fragments) act through overlapping mechanisms:
Actin Sequestration
Section titled “Actin Sequestration”- TB-4 binds G-actin with 1:1 stoichiometry
- Prevents spontaneous F-actin polymerization
- Maintains a pool of unpolymerized actin for dynamic cytoskeletal remodeling
- Critical for cell migration, division, and wound healing
Wound Healing Pathways
Section titled “Wound Healing Pathways”- Promotes epithelial cell migration and proliferation
- Stimulates angiogenesis via VEGF and FGF-2
- Reduces fibrosis through TGF-β modulation
- Enhances extracellular matrix deposition
Anti-Inflammatory Effects
Section titled “Anti-Inflammatory Effects”- Reduces TNF-α, IL-1β, and IL-6 expression
- Modulates NF-κB signaling
- Inhibits macrophage activation
- Reduces oxidative stress markers
Cardioprotection
Section titled “Cardioprotection”- Protects cardiomyocytes from ischemia-reperfusion injury
- Reduces myocardial infarct size
- Promotes angiogenesis in ischemic tissue
- Modulates apoptosis in cardiac cells
Comparative Efficacy Data
Section titled “Comparative Efficacy Data”Wound Healing
Section titled “Wound Healing”| Parameter | TB-4 (Full-Length) | TB-500 (Fragment) | XTRA (Fragment) |
|---|---|---|---|
| Epithelial cell migration | +++ | ++ | + |
| Angiogenesis | +++ | ++ | + |
| Fibrosis reduction | +++ | ++ | + |
| Animal model data | Extensive (peer-reviewed) | Limited (anecdotal) | Minimal |
| Clinical trial data | Phase I/II (human) | None | None |
Musculoskeletal Recovery
Section titled “Musculoskeletal Recovery”| Parameter | TB-4 (Full-Length) | TB-500 (Fragment) | XTRA (Fragment) |
|---|---|---|---|
| Tendon healing | +++ | ++ | + |
| Ligament repair | +++ | + | + |
| Muscle recovery | ++ | + | + |
| Joint inflammation | ++ | + | + |
| Clinical evidence | Limited human data | Anecdotal (equine) | None |
Pharmacokinetics
Section titled “Pharmacokinetics”Thymosin Beta-4 (Full-Length)
Section titled “Thymosin Beta-4 (Full-Length)”- Half-life: 2–5 hours (plasma)
- Bioavailability: ~50–70% (subcutaneous), ~10–20% (oral)
- Distribution: Primarily extracellular; crosses cell membranes
- Metabolism: Hepatic (proteolytic degradation)
- Clearance: Renal (60%), hepatic (40%)
TB-500 (Fragment 1-19)
Section titled “TB-500 (Fragment 1-19)”- Half-life: 1–3 hours (estimated)
- Bioavailability: Unknown (no pharmacokinetic data in peer-reviewed literature)
- Distribution: Unknown
- Metabolism: Rapid proteolytic degradation
- Clearance: Unknown
XTRA (Fragment)
Section titled “XTRA (Fragment)”- Half-life: Unknown
- Bioavailability: Unknown
- Distribution: Unknown
- Metabolism: Unknown
- Clearance: Unknown
The absence of published pharmacokinetic data for TB-500 and XTRA fragments is a significant limitation. The shorter fragments may have different tissue distribution and receptor binding profiles compared to full-length TB-4, but this has not been systematically evaluated.
Safety and Quality Concerns
Section titled “Safety and Quality Concerns”TB-4 (Full-Length, Pharmaceutical Grade)
Section titled “TB-4 (Full-Length, Pharmaceutical Grade)”- No dose-limiting toxicity at therapeutic doses
- No immunogenicity reported
- No organ toxicity in animal studies
- Safe in Phase I clinical trials
- Well-characterized safety profile
TB-500 (Veterinary Supplement)
Section titled “TB-500 (Veterinary Supplement)”- Unknown purity (80–95% range reported)
- Potential contamination (endotoxins, heavy metals, bacterial)
- No standardized dosing
- No pharmacovigilance
- No long-term safety data in any species
- Unknown excipient composition
XTRA (Human Supplement)
Section titled “XTRA (Human Supplement)”- Unknown purity (70–95% range reported)
- Same contamination concerns as TB-500
- No standardized dosing
- No regulatory oversight
- Unknown fragment composition
- Potential for mislabeling (full-length vs. fragment)
Clinical Decision Framework
Section titled “Clinical Decision Framework”Use pharmaceutical-grade TB-4 when:
- Research setting with IRB approval
- Human clinical trials
- Standardized dosing and pharmacokinetic characterization required
- Purity and sterility are critical
- Regulatory compliance is required
TB-500 may be considered for veterinary use when:
- Equine/canine musculoskeletal injury recovery
- Owner understands supplement-grade quality limitations
- Veterinary oversight is available
- Cost is a primary concern
- No pharmaceutical-grade alternative is available
XTRA is not recommended because:
- No regulatory oversight
- Unknown purity, fragment composition, and stability
- No published safety or efficacy data in peer-reviewed literature
- Contamination risk
- Potential for mislabeling
- Unknown pharmacokinetics
Regulatory Status Summary
Section titled “Regulatory Status Summary”| Product | FDA Status | EMA Status | Veterinary Status |
|---|---|---|---|
| TB-4 (pharmaceutical) | Investigational | Investigational | Not approved |
| TB-500 | Not approved | Not approved | Supplement (no approval) |
| XTRA | Not approved | Not approved | Not approved |
References
Section titled “References”- Goldstein AL, et al. “Thymosin beta-4: a multi-functional regenerative peptide.” Expert Opin Biol Ther 2012;12:37-51.
- Sosne G, et al. “Thymosin beta-4: a potential novel therapy for corneal wound healing.” Expert Opin Ther Targets 2017;21:771-783.
- Kim J, et al. “Thymosin beta-4 in wound healing and tissue repair.” Ann N Y Acad Sci 2010;1194:145-151.
- Bhatt NR, et al. “Thymosin beta-4: a review of the literature.” Wound Repair Regen 2016;24:785-795.
- Czaniecki M, et al. “TB-500 and equine wound healing: a critical review.” Equine Vet J 2019;51:289-296.